Open access

27 Defining elite macrophages from tumor-on-a-chip
Yang Xiang, Xiaohan Feng

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A29; DOI: 10.1136/jitc-2023-SITC2023.0027
3 External reproducibility of PD-L1 IHC 22C3 pharmDx for colorectal carcinoma specimens at CPS ≥ 1 cutoff
Lining Hutchinson, Armita Bahadori, Megan Kalpakoff, Francisco Ponce, Siena Tabuena-Frolli, Kristopher Kersch, Monika Polewski

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A3; DOI: 10.1136/jitc-2023-SITC2023.0003
28 Toward an automated microfluidic platform for monitoring immune response to immunotherapy
Yuqian Zhang, Yohan Kim, Fabrice Lucien-Matteoni, Haidong Dong, Yuguang Liu

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A30-A31; DOI: 10.1136/jitc-2023-SITC2023.0028
29 Immune modulation and baseline biomarker correlation with clinical benefit following treatment with COM701+nivolumab+/-BMS-986207 in patients with platinum resistant ovarian cancer
Gady Cojocaru, Zoya Alteber, Assaf Wool, Adi Shuchami, Inbal Barbiro, Roy Granit, Yu Liang, Zurit Levine, Pierre Ferre, Eran Ophir

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A32-A34; DOI: 10.1136/jitc-2023-SITC2023.0029
30 Molecular features associated with long survival on tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial
Marlana Orloff, Kevin Kim, Sarah Stanhope, Adel Benlahrech, Emma Leach, Laura Collins, Koustubh Ranade, Brendan Curti

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A35; DOI: 10.1136/jitc-2023-SITC2023.0030
31 Development of GMP serum-free cryopreservation solutions for human T cells and mesenchymal stem cells
Zayda Piedra, David Cruz, Jessie Ni

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A36; DOI: 10.1136/jitc-2023-SITC2023.0031
32 Identification of predictive biomarkers of clinical response to PD-1 blockade in patients with advanced non-small cell lung cancer
Nikita Dutta, Ella Eklund, Levent Akyürek, Per Torstensson, Volkan Sayin, Anna Rohlin, Andreas Hallqvist, Sukanya Raghavan

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A37; DOI: 10.1136/jitc-2023-SITC2023.0032
33 Blood-based tumor mutation burden (bTMB) predicts response to immune checkpoint blockade-based combination therapy (ICBC) in advanced non-small cell lung cancer (NSCLC): a real-world (RW) analysis
Sean Gordon, Bruna Pellini, Reagan Barnett, Jiemin Liao, Katie Quinn, Sara Wienke, Leylah Drusbosky, Nicole Zhang, Martina Lefterova, Lauren Lawrence, Lesli Kiedrowski, Ross Eppler, Justin Odegaard, Han-Yu Chuang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A38; DOI: 10.1136/jitc-2023-SITC2023.0033
34 Association of a novel circulating tumor fraction DNA biomarker of treatment response monitoring and clinical outcomes in a real-world, diverse pan-cancer cohort treated with immunotherapy
John Guittar, Ryan Gentzler, Akash Mitra, Michelle M Stein, Christine Lo, Wei Zhu, Terri Driessen, Justin Guinney, Halla Nimeiri, Rotem Ben-Shachar, Jyoti Patel

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A39; DOI: 10.1136/jitc-2023-SITC2023.0034
4 Combinations of immune checkpoint inhibitors with fractionated radiotherapy or DNA damage response agents leads to improved anti-tumour responses and modulates the tumour immune microenvironment
Charlotte Bell, Theoni Katopodi, Yin Xin Ho, Pablo Binder, Tobias Bunday, Emily Wright, Amy Cantrell, Nick Moore, Stewart Brown, Paul Farrington, Shannon Sharman, Lyndsey Hanson, Lorraine Mooney, Jane Kendrew

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A4; DOI: 10.1136/jitc-2023-SITC2023.0004

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages